Developments in targeted therapy of advanced gastrointestinal stromal tumors.

Developments in targeted therapy of advanced gastrointestinal stromal tumors. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Developments in targeted therapy of advanced gastrointestinal stromal tumors. Abstract Text:

Gastrointestinal stromal tumors (GISTs) comprise a recently defined entity of the most common mesenchymal neoplasms of the gastrointestinal tract. Advances in the understanding of the molecular mechanisms of GIST pathogenesis have resulted in the development of a treatment approach which has become a model of targeted therapy in oncology. The introduction of imatinib mesylate (inhibiting KIT/PDGFRA (platelet-derived growth factor receptor-alpha) and their downstream signaling cascade) has revolutionized the therapy of advanced (inoperable and/or metastatic) GISTs. Imatinib has now become the standard of care in the treatment of patients with advanced GIST. However, a majority of patients eventually develop clinical resistance to imatinib. Over the last few years major progress has been made in elucidating the mechanism of disease progression (as secondary mutations in KIT and/or PDGFRA kinase domains) and resistance to imatinib. Currently, the sole approved second-line drug is sunitinib - a multitargeted agent, an inhibitor of tyrosine kinase, of KIT and PDGFRA/B and of the vascular endothelial growth factor receptors (VEGFRs)-1, -2 and 3, FMS-like tyrosine kinase-3 (FLT3), colony stimulating factor 1 receptor (CSF-1R), and glial cell-line derived neurotrophic factor receptor (REarranged during Transfection; RET). However, a number of new generation tyrosine kinase inhibitors, alone or in combination, are being evaluated at present alongside treatment options alternative to inhibiting the KIT signaling pathway (as heat shock protein 90 or mammalian target of rapamycin). This article discusses the factors relating to imatinib resistance as well as upcoming potentially effective treatment options for patients with progressive disease available in 2008 and those under investigation with more individualized treatment methods, which has been recently patented. This review focuses on the current achievements in targeted therapy of advanced GISTs, and how the insight into the resistance mechanisms may allow in the near future to treat patients with advanced GISTs.

Developments in targeted therapy of advanced gastrointestinal stromal tumors. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Developments in targeted therapy of advanced gastrointestinal stromal tumors. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Recent patents on anti-cancer drug discovery

VOLUME: 3

Page Numbers: 88-99

Journal Abbreviation:

ISSN: 1574-8928

DAY: 9

MONTH: Jun

YEAR: 2008

Developments in targeted therapy of advanced gastrointestinal stromal tumors. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101266081

Developments in targeted therapy of advanced gastrointestinal stromal tumors. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Developments in targeted therapy of advanced gastrointestinal stromal tumors. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Developments in targeted therapy of advanced gastrointestinal stromal tumors.

AFFILIATION: Department of Soft Tissue/Bone Sarcoma and Melanoma; Department of Anesthesiology; Department of Molecular Biology; M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology; Warsaw, Poland. rutkowskip@coi.waw.pl.

Country: United Arab Emirates

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Recent Patents Anticancer Drug

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Developments in targeted therapy of advanced gastrointestinal stromal tumors Related Publications

• An individual difference analysis of false recognition.
• Atomic force microscopy visualization of poly(urethane urea) microphase rearrangements under aqueous environment.
• Developments in targeted therapy of advanced gastrointestinal stromal tumors.
• Effects of surface wettability and contact time on protein adhesion to biomaterial surfaces.
• Efficiency of route selection as a function of adult age.
• Immunological identification of fibrinogen in dual-component protein films by AFM imaging.
• Late complications at repair site of operated coarctation of aorta.
• Measuring the time-dependent functional activity of adsorbed fibrinogen by atomic force microscopy.
• Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection.
• Normal pressure hydrocephalus: are you missing the signs?
• Procoagulant activity of surface-immobilized Hageman factor.
• [Diagnostic difficulties in osteoarticular tuberculosis]
• [Head lift test in assessment of recovery from muscle paralysis after administration of curare in adults]
• [Results of chemotherapy with bleomycin and vinblastine of malignant testicular neoplasms at the Warsaw Institute of Oncology in the years 1977-1978]